BCMA/CD19 dual-target CAR-T cells (fourth-generation)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BCMA/CD19 dual-target CAR-T cells (fourth-generation), covering 2024-10-15 to 2024-10-15. Get the full timeline:
Most recent: Clinical Trial Update: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]